Innate Pharma's Lacutamab Gets FDA Green Light

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded10 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2198456

Show notes

Innate Pharmas stock surged by 23% following FDAs review of lacutamab, a new drug for skin lymphomas. The FDAs silence on the Phase Three study is a positive sign. Innate Pharma plans to start the TELLOMAK Three trial in H1 2026, focusing on Sézary syndrome and Mycosis fungoides patients. Positive early feedback from the FDA could lead to accelerated approval for Sézary syndrome.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.